January 2012
Afexa Announces Results of a Clinical Trial of Dilexaponan™ for Cholesterol Management - Marketwire.com
EDMONTON, ALBERTA--(Marketwire - Aug. 18, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX® - today announced promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan™ (LIP-01) on cholesterol management. Dilexaponan is a proprietary polymolecular formulation isolated from botanical sources and developed and standardized using ChemBioPrint technology.
More supplement makers spending big money on rigorous research - sltrib.com
Brent Bauer, an internist at the Mayo Clinic, noticed something strange in recent years about the clinic’s arthritis patients. Some reported no longer needing their steroid medications after drinking a juice produced from an obscure fruit.
Bauer began wondering whether there really is something to the mangosteen. This tropical berry is used in expensive supplement beverages sold through multilevel marketing programs, including Utah’s XanGo, that claim anti-inflammatory properties and other health benefits.
Popsi Cube using iPhones for blood pressure data tracking - outsourcing-pharma.com
CRO Popsi Cube is using iPhones to track blood pressure data and send questionnaires to patients.
France-based Popsi Cube is using technology created by Withings, a developer of health technology, to provide the service, called Popsicare. The system links a blood pressure monitor to an iPhone or iPad for handling of the data.
Electronic Informed Consent: Types and Technologies - rebarinteractive.com
Wondering if electronic informed consent is right for your clinical research study? My 2-part series will help you answer that question.
Mitchell Parrish of Quorum IRB recently led a webinar about electronic informed consent, which included discussion of regulatory and other considerations. In this series, I summarize the information presented by Parrish, as well as provide some additional commentary.
CROs (slowly) piece together EFSA's health claim science puzzle - nutraingredients.com
In the second part of this special series on global outsourcing trends NutraIngredients explores how the European Union nutrition and health claims regulation (NHCR) is impacting activity in the contract research organisation (CRO) sector.
The controversial legislation is changing the relationship between nutrition science and food and food supplements marketing due to the fact so much nutrition science that previously informed health food messaging is being ruled inadmissible by the EU's head science agency.
Clinical trial success: Design and recruitment - www.nutraingredients.com
Designing a clinical trial correctly from the beginning is the most important issue for success, while a ready supply of volunteers for natural product clinical trials takes the pressure off patient recruitment, says the CEO of a CRO.
Speaking with NutraIngredients, Dr Jay Udani, CEO of Medicus Research, a California-based clinical research organisation (CRO) with expertise in natural products, explained that when it came to dietary supplement and nutraceutical clinical trials, the biggest challenge and most important factor for success is designing
Clinical trial success: Patient compliance - nutraingredients.com
A good relationship with clinical trial participants is crucial in making sure they are compliant to the protocol of a study, says the CEO of a CRO.
Speaking with NutraIngredients, Dr Jay Udani, CEO of Medicus Research, a California-based clinical research organisation (CRO) with expertise in natural products, explained that when it comes to compliance, the first and most important thing is having a good relationship with the patient.